The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.

The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.

The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.

The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.

The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.

The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.

Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.

The present invention provides a structure suitable for controlling the release quantity of an active ingredient in a state where the structure is in contact with skin. A structure 10 according to the present invention includes a retention part 1 that retains an active ingredient, and a release control layer 3 that controls release of the active ingredient to an outside. In the structure 10, at least one of the following conditions holds: i) the release control layer 3 includes a microporous membrane having an average pore diameter of 0.01 μm or less; and ii) the release control layer 3 is a nanofiltration membrane or a reverse osmotic membrane.

Disclosed is a storage stable pharmaceutical composition containing at least one active pharmaceutical ingredient selected from peptides of the general formula 1 [SEQ ID NO: 1-144] or peptides of the general formula 2 [SEQ ID NO: 145-288], or, their derivatives, analogs or pharmaceutically acceptable salts, or co-crystals of these peptides, their derivatives or analogues; and a pharmaceutically acceptable carrier, wherein the composition retains at least 80% of the potency of active pharmaceutical ingredient in the pharmaceutical composition after storage for at least four months at room temperature. Also, disclosed are process for their preparation and methods of use.

Disclosed is a storage stable pharmaceutical composition containing at least one active pharmaceutical ingredient selected from peptides of the general formula 1 [SEQ ID NO: 1-144] or peptides of the general formula 2 [SEQ ID NO: 145-288], or, their derivatives, analogs or pharmaceutically acceptable salts, or co-crystals of these peptides, their derivatives or analogues; and a pharmaceutically acceptable carrier, wherein the composition retains at least 80% of the potency of active pharmaceutical ingredient in the pharmaceutical composition after storage for at least four months at room temperature. Also, disclosed are process for their preparation and methods of use.